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mission 
 
To provide an integrated, person centred, specialist addiction service, supported by best practice and 
national leadership in academic excellence.  
 
vision 
 
As the largest and longest established national addiction treatment (Day) centre in the country, our aim is to 
continue providing a broad range of specialist treatments for a variety of drug using populations and those 
requiring specialist psychiatric, psychological, social and medical interventions. We also aim to:  
 
 continue improving and developing the services we offer in the treatment of substance misuse 
 contribute to drug treatment policy and  
 act as a key resource and training centre for professionals working in the area of substance misuse. 
 
As a specialist service we contribute to forward thinking policies for the treatment, prevention, education, 
rehabilitation, aftercare, and the development of adequate programmes of care for those affected by 
substance misuse. 
 
In collaboration with educators, other statutory, voluntary and community agencies, we strive to foster a 
spirit of independence and choice amongst clients, developing and promoting best practice in therapeutic 
and clinical treatments. 
 
Research is an integral part of assessing the effectiveness of existing practices and appropriate policy 
development. We support this by producing data on evidence-based research. Our specialist service also 
provides evidence-based practice which supports insight into the effectiveness of current treatments and 
best practice within the addiction field. As such, and as a hub of addiction services, we aim to lead and 
inform on best practice and to contribute to drug treatment policy.  
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about 
The Drug Treatment Centre Board (DTCB)  
 
The Drug Treatment Centre Board, formerly known as The National Drug Advisory and Treatment Centre, 
was established in 1969 and is the longest established treatment service in the country.  It was originally 
located at the ‘Charitable Infirmary’, Jervis Street Hospital, Dublin 1, established in 1718.  The current 
Chairman of our Board is Mr. Dan McGing.  At the end of 1987, Jervis Street Hospital closed.  The Drug 
Treatment Centre Board was set up by statutory instrument in 1988 and moved to new premises at 
McCarthy Centre, 30 – 31 Pearse Street, Dublin 2.  We receive our funding from the Health Service 
Executive. 
 
We are committed to providing effective, high quality and client focused treatment. This is provided in a 
caring, professional manner, taking account of the individual needs of our clients within a multidisciplinary 
setting. We offer guidance and training to other professionals working in the area of substance misuse and 
contribute to policy development in addiction management.  
 
In partnership with other statutory and voluntary agencies, The Drug Treatment Centre Board provides 
prevention, treatment, rehabilitation and aftercare programmes on an out-patient and in-patient basis in 
order to minimise the harmful effects of drug addiction and prevent the spread of HIV and other infectious 
diseases. 
 
Out-patient treatment facilities are provided on-site. In-patient detoxification facilities are located at St. 
Michael’s Ward, Beaumont Hospital, Dublin (10-bed unit) and Cuan Dara, Cherry Orchard Hospital, 
Dublin (17-bed unit). 
 
In addition we provide a National Drug Analysis Laboratory service which supports treatment policy, 
monitors trends and supports service planning and best practice in the treatment, care and management of 
drug misuse. Our research supports evidence based practice in drug treatment policy and clinical 
developments. 
 
Specialist Clinical Services on-site include: 
General Medical and Psychiatric Assessment 
 Dual Diagnosis Clinic 
 Adult Attention-Deficit Hyperactivity Disorder (ADHD) Clinic 
 On site Hepatitis C Treatment Service 
 On site HIV treatment (in conjunction with St. James’s Hospital) 
 Prevention and Treatment of Viral Infections 
 Primary Care Services 
 Sexual Health Clinic 
 Liaison Midwifery Services 
 Treatment Programmes – Polysubstance misuse 
 Young Persons Programme (YPP) (18 years and under) 
 Advisory services to other professionals 
 
Other Services 
 Counselling and Family Support Services  
 Social Work Services  
 Specialised groups for cocaine and alcohol misuse 
 Welfare Services 
 Complementary Therapies 
 Outreach Services  
 In-House Play Room Services  
 Literacy Classes 
 Research 
 Central Treatment List 
 National Drug Analysis Laboratory  
 Occupational Health Services 
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Board Members 
 
 
 
 
Mr. Dan McGing Chairman 
Prof. Joseph Barry Board Member 
Dr. Íde Delargy Board Member 
Prof. Kieran Taaffe Board Member 
Dr. John O’Connor Board Member 
Dr. Siobhan Rooney Board Member  
Mr. Liam O’Brien Board Member  
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Chairman’s Statement  
 
It gives me great pleasure to introduce our Annual Report 2011 which provides an informative 
account of our activities.    
 
I would like to acknowledge the ongoing commitment of our Chief Executive Sheila Heffernan 
and our senior management team and staff in the continued delivery of a quality service.  On 
behalf of the Board I would like to acknowledge them and their work in what continues to be an 
ever changing and demanding environment.   
 
In 2010 we saw the sad passing of our Chairman Denis P. McCarthy. In 2011 in his honour our 
Board renamed our building to the McCarthy Centre. We think this is a fitting tribute to a man 
and family who have been synonymous with our Board, The Charitable Infirmary Charitable 
Trust and the former Jervis Street Hospital.   
 
In late 2008 the then Minister for Finance the late Brian Lenihan announced Governments 
intention to merge The Drug Treatment Centre Board with the Health Service Executive. We are 
working with all stakeholders in ensuring that the many years of hard work and dedication to 
those we serve continues to grow and develop into the future.  
 
Our Ethics Committee continues its work and includes representation from medical, legal, 
nursing, management and lay people. The Board acknowledges their support, dedication and 
commitment under the Chairmanship of Justice Donachda O’Buchalla. On behalf of our Board I 
would like to acknowledge his work and commitment and that of his voluntary committee. 
 
As part of our work we continue to contribute to research. We have worked with the Department 
of Health on the establishment and management of a National Suboxone List. In taking 
responsibility for the management of this national list further demonstrates our capabilities and 
we consider this work vital in the development of additional treatment interventions. 
 
Despite tightening budgetary constraints we continue to deliver a quality service to our clients 
and families. Into the future with the planned merge of our Board with the HSE we look forward 
to continuing to work in the delivery of a quality specialist drug treatment service. As we move 
into our forty third year we are confident that the level of expertise and knowledge developed by 
our Board, management and staff will continue to contribute to providing quality specialist 
addiction services nationally.   
 
On behalf of the Board, I would like to thank the Charitable Infirmary Charitable Trust, The 
Department of Health and The Health Service Executive for their continued support. We are 
fortunate to have a dynamic, focused and committed team of managers and staff. Under the 
guidance of the Board and Chief Executive Officer, Sheila Heffernan, this team enables us to 
build on our success. I would like to congratulate my Board colleagues, management and staff for 
a job well done! 
 
 
 
Dan McGing  
Chairman                         
30
th
 June 2012 
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Chief Executive Officer’s Report 
 
 
During the past number of years the key documents that continue to underpin the strategies and 
plans for our Board are The Health Strategy, Quality and Fairness – A Health System for You, 
The Way Home – A Strategy to Address Adult Homeliness in Ireland (2008-2013 – Environment, 
Heritage & Local Government), the National Drugs Strategy 2009-2016 and The Introduction of 
the Opioid Treatment Protocol (2010). We continue to build on our existing services through 
programmes of improved quality whilst leading and informing on best practice.   
 
This year we are reporting through our Electronic Patient System (EPS). In 2011 1,763 
individuals availed of our services. There was no significant change in the age profile of clients 
attending our services with the ratio of males to females remaining at 2:1. The number of young 
people under the age of 20 who entered treatment in 2011 was 37.     
 
Highlights of our recent achievements include:- 
 
 Maintaining our accreditation to the ISO/IEC 17025 standard for our national laboratory 
services 
 Expansion of our web-based system of Laboratory Electronic Reporting (LER) was made 
available to more of our customers in 2011. The system provides customers with an 
option to access their results on line.  
 In response to the recommendation of The Review of the Opioid Treatment Protocol 
(2010) to move towards oral fluid testing, in 2011 we validated immunoassay screening 
methods for the detection of drugs in Oral Fluid  including Opiates, 6-AM (Heroin 
Metabolite), Cocaine, Cannabinoids (Cannabis), Amphetamine and its derivatives, 
Benzodiazepines. 
 In 2011 we also validated an immunoassay method for Ethyl Glucuronide in urine. Ethyl 
glucuronide (EtG) is a direct metabolite of ethanol and can be detected several days after 
the elimination of alcohol from the body thus increasing the window of detection of 
alcohol use.   
 Continued development of our bespoke Electronic Patient System (EPS) in conjunction 
with the Health Service Executive. 
 Completion of a pilot programme EPS x 
 Involvement in international and national trails in respect of suboxone treatment which 
included the design and development of a suitable national IT database.   
 In 2011 we conducted 80 walk in initial/emergency assessments. Benefits include direct 
access to assessment services for drug users and an opportunity to plan appropriate 
services based on client needs. 
 There were 1,694 visits to our children’s play room. 
 Our Ethics Committee meets every quarter to review and adjudicate various research 
proposals. 12 proposals were considered in 2011.  
 The number of clients identifying themselves as homeless continues to increase year on 
year from 181 in 2007 to 233 in 2011. This represents is an increase of 28.7 %. 
  
The development of our Electronic Patient System (EPS) has continued over the years. In 2011 a 
feasibility study concerning the development of our system as the national HSE standard for care 
planning within addiction services was undertaken.  
The aim of this project was to pilot our EPS electronic health record in accordance with the 
recommendations contained in The Introduction of the Opioid Treatment Protocol: (HSE, 
2010:34) to determine its compatibility and potential use by community drug treatment services. 
In this way identified national problems concerning fragmented and demarcated provision of 
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services which militate against HSE and NDS policy concerning the need for greater integration 
and continuity of care by adopting shared care planning and the development of integrated care 
pathways, can be addressed. It recommends that the EPSx system be rolled out nationally 
across all addiction services, based on the existing service provider model, which is deemed 
fit for purpose from practice and technical perspectives. In 2012 we look forward to 
progressing this project nationally. 
 
On behalf of the Board, management and staff, I would like to thank the Charitable Infirmary 
Charitable Trust, the Department of Health, the Health Research Board, the State Claims Agency 
and the HSE for their continued support.  We share their objective to improve the patient/client 
journey and provide a better working environment for staff.  I would also like to acknowledge St. 
James’s Hospital, Cuan Dara, Cherry Orchard Hospital and St. Michael’s Ward, Beaumont 
Hospital as well as our many partners in the Voluntary and Statutory sector, the local community, 
businesses and other community service providers.  
 
The dedication of our building name in recognition of our past Chairman Denis P McCarthy I feel 
is a fitting tribute to the hard work, dedication and commitment he showed during his time on the 
Board.  
 
I would like to thank our current Board Members under the Chairmanship of Dan McGing and 
our staff for their continued commitment, innovation and dedication to providing high quality 
client centred services. I look forward to continuing to work with all into the future. 
 
Sheila Heffernan 
Chief Executive Officer 
30
th
 June 2012 
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Clinical Director’s Report 
 
 
In collaboration with my Consultant colleagues, Dr. Eamon Keenan, Dr. Brion Sweeney, Dr. 
Siobhán Rooney, Dr. Bobby Smyth, Dr. Gerry McCarney and Dr. Mike Scully we continued to 
work closely in the provision of the best service possible. 
 
We provide external psychiatric assessments on behalf of Cuan Dara, Cherry Orchard Hospital, 
St. Michael’s Ward, Beaumont Hospital, the Rutland Centre, Dublin and the Health Service 
Executive. This service supports the initiation of appropriate treatment interventions and 
facilitates clients care to be managed at a local level. We also continue to provide twenty-four 
hour medical cover to St. Michael’s Ward, Beaumont Hospital and Cuan Dara, Cherry Orchard 
Hospital. 
 
I would like to concur with our Chairman and Chief Executive Officer in acknowledging the hard 
work and dedication of the late Chairman of our Board Mr. Denis McCarthy who served our 
Board relentlessly in the interest of our clients and staff. I would also like to acknowledge the 
hard work and dedication of our Board Members under the chairmanship of Dan McGing I am 
confident that the achievements of the last forty two years will be built upon going forward as we 
plan to merge with the Health Service Executive.  
 
The ongoing dedication of The Drug Treatment Centre Board senior management team under the 
direction of our Chief Executive Officer Ms Sheila Heffernan, our staff and the staff of St. 
Michael’s Ward, Beaumont Hospital and Cuan Dara, Cherry Orchard Hospital is very much 
appreciated. 
    
I look forward to working with all into the future. 
 
 
Dr. John O’Connor 
Clinical Director 
Consultant Psychiatrist in Substance Misuse 
30
th
 June 2012 
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Trends 2011 
 
 
Treatment Services 
 2011 
 
Number of clients who received 
services 
 
 
1,763 
 
 
Number of related attendances 
 
 
93,527 
 
Male/Female Ratio 
 
 
2:1 
Source: Electronic Patient Record (EPS). The Drug Treatment Centre Board 
 
In 2011, 1,763 individuals attended for services, of which 864 entered into our treatment 
programmes. The remaining 899 individuals received a range of services including, psychiatric, 
psychological and social interventions, primary healthcare, counselling, crisis support, advice and 
information, needle exchange, health promotion services, family support and children’s playroom 
services.  The ratio of males to females remains circa 2:1. 
 
We also provide a national advisory and support service to professionals involved in the 
treatment, care and management of drug misuse. This is further supported through the 
dissemination of policies, procedures and protocols in relation to best practice, medical and 
therapeutic interventions.  
 
Number of Clients who Received in-patient Medical Management in 2011 
In-Patient Facility No. of Clients 
St. Michaels Ward, Beaumont Hospital 134 
Cuan Dara, Cherry Orchard Hospital    155 
Total 289 
 
Specialist Clinical Services  
Psychiatric and General Medical Assessment  
Dual Diagnosis Clinic 
On site HIV treatment (in conjunction with St. James’s Hospital) 
On site Hepatitis C treatment programme 
Prevention and Treatment of Viral Infections 
Liaison Midwifery  
Sexual Health Clinic 
Adult Attention-Deficit Hyperactivity Disorder (ADHD) Clinic 
  
Medical Treatment Services  
Detoxification (in-patient and out-patient) 
Methadone Maintenance Programmes 
Stabilisation Programmes 
Primary Care  
Blood Borne / Virus Disease Surveillance 
Harm Reduction Programme 
Warfarin Clinic 
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Gender Profile for cases assessed or treated 2011 
 
 
 
 
 
 
 
 
 
Source: Electronic Patient Record (EPS) The Drug Treatment Centre Board 
 
 
 
  
Age Profile 2011 
 
 2011 % 
20 and 
under 
 
37 
 
4 
21-25 84 10 
26-30 197 23 
31-35 340 40 
6-40 52 6 
41-45 89 10 
46-50 44 5 
51-55 18 2 
56 years and 
over 
3 0 
Total 864 100 
Source: Source: Electronic Patient Record (EPS) The Drug Treatment Centre Board 
 
 
 
Living status of cases assessed or treated in 2011 
 
 2011 
Living status Count %  
Stable accommodation 553 64 
Institution (prison, residential care, halfway 
house) 
11 1 
Homeless 233 27 
Other unstable accommodation 43 5 
Not known 24 3 
Total 864 100 
Source: Source: Electronic Patient Record (EPS) The Drug Treatment Centre Board 
 
 
The number of clients identifying themselves as homeless continues to increase year on 
year from 181 in 2007 to 233 in 2011. This represents is an increase of 28.7 %. 
 
 2011 
Gender Count % 
Male 588 68 
Female 276 32 
Total 864 100 
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Central Treatment List 
The Central Treatment list (CTL) is a confidential database managed by our Board. In October 
1998, specific legislation was introduced making it a requirement for all clients in receipt of 
methadone treatment to be on a national register. The maintenance of the list complies with the 
provisions of the Data Protection Acts, 1998 & 2003.  
 
A total of 10,711 clients were in receipt of methadone and 82 clients were in receipt of Suboxone 
treatment during 2011 in Ireland.  
 
We continue to enhance our IT system. This helps with identifying and addressing gaps in service 
provision having regard to evidence available. The CTL is also a valuable resource providing 
information to the National Drug Related Death Index (NDRDI). It continues to be a key 
mechanism to other agencies as a resource for professionals in the treatment, care and 
management of drug misuse nationally.  
 
In 2009 we developed a database for a Suboxone Feasibility Study in partnership with the 
Department of Health and the Health Service Executive. The database will provide valid, timely 
& comparable data to stakeholders. 
 
The Introduction of the Opioid Treatment Protocol (December, 2010) has identified a number of 
enhancements required to the Central Treatment List databases. During 2011 we commenced 
actively working to ensure successful implementation of its recommendations.   
 
Number of Clients Receiving Methadone in Ireland 
Central Treatment List 
 
 
Source: The Drug Treatment Centre Board, Central Treatment List 
 
Number of Clients Receiving Suboxone in Ireland 
Central Treatment List 
 
 
 
 
 
Source: The Drug Treatment Centre Board, Central Treatment List 
 
 
 
Year Total No of Clients % +/- 
 
2001 
 
7107 
 
 
2002 
 
7596 
 
+6.88% 
 
2003 
 
8155 
 
+7.36% 
 
2004 
 
8364 
 
+2.56% 
 
2005 
 
8962 
 
+7.15% 
 
2006 
 
9428 
 
+5.20% 
 
2007 
 
9760 
 
+3.52% 
 
2008 
 
10,213 
 
+4.65% 
 
2009 
 
10,668 
 
+4.46% 
 
2010 
 
10,787 
 
+1.1% 
 
2011 
 
10,711 
 
-0.7% 
Year Total No of Clients 
 
2011 
 
82 
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National Drug Analysis Laboratory  
 
Our laboratory is the leading centre for drugs of misuse testing in Ireland.  With over 40 year’s 
experience, we are the largest specialist provider of drugs of abuse screening for drug treatment 
services nationally. We provide a nationwide service to the HSE Addiction Services, Hospitals, 
General Practitioners, Voluntary Organisations, Department of Education (juvenile detention 
centres), the Probation Service, the Courts Service, the Medical Council, an Bord Altranais and 
various occupational health departments.  
 
We are a highly efficient laboratory and conducted over 1 million immunoassay screening tests 
and circa 21,000 drugs screened for using confirmatory analyses in 2011. We also actively 
participate on the Early Warning and Emerging Trends (EWET) Committee of National Advisory 
Committee on Drugs.  
 
Analytical techniques used by the laboratory include Immunoassay, Liquid Chromatography – 
Mass Spectrometry (LC-MS), Gas Chromatography-Mass (GC-MS) and Enzyme-Linked 
ImmunoSorbent Assay (ELISA). 
 
We are accredited by the Irish National Accreditation Board (INAB) to ISO/IEC 17025 standard. 
The scope of our Accreditation covers toxicology screening by immunoassay of Opiates, 6-AM 
(Heroin Metabolite), Cocaine, Cannabinoids (Cannabis), Amphetamine and its derivatives, 
Benzodiazepines, EDDP (Methadone Metabolite), Alcohol, pH and Creatinine. (INAB scope 
169T).  
 
In response to the recommendation of The Review of the Opioid Treatment Protocol (2010) to 
move towards oral fluid testing, in 2011 we validated immunoassay screening methods for the 
detection of drugs in Oral Fluid  including Opiates, 6-AM (Heroin Metabolite), Cocaine, 
Cannabinoids (Cannabis), Amphetamine and its derivatives, Benzodiazepines. 
 
In 2011 we also validated an immunoassay method for Ethyl Glucuronide in urine. Ethyl 
glucuronide (EtG) is a direct metabolite of ethanol and can be detected several days after the 
elimination of alcohol from the body thus increasing the window of detection of alcohol use.   
 
Our range of routine confirmatory analysis in urine includes Opiates, Zopiclone, 
Benzodiazepines, Buprenorphine and Cannabinoids. Multiresidue methods to screen for 
Stimulants including amphetamines, ecstasy type drugs and “Head Shop” drugs including 
cathinones and other stimulants are available. Methods have also been developed for the analysis 
of Z drugs, Crack Cocaine, Mirtazepine and Olanzapine. 
 
Our ‘Head shop’ Screen is subject to change as required but currently includes the following 
drugs: 
 
Dimethyl Cathinone, Naphyrone, Dimethocaine, 3-Fluoromethcathinone, 4-
Methylethcathinone (4-MEC), 4-Ethylmethcathinone (4-EMC), 3,4-
Dimethylmethcathinone (3,4 DMMC), Butylone, Ethylone, Naphyrone, Pentylone, 
Ethcathinone, O-Desmethyltramadol, MDPV, Methedrone, 3TFMPP, Tramadol, BZP, 
mCPP, PCat, 2-Aminoindane, 5,6-Methylenedioxy-2-aminoindane (MDAI), 2-
Phenethylamine, Mephedrone, Methylone, Methedrone,  Synephrine, Buphedrone, 3,4 
Methylenedioxy-alpha-pyrrolidinobutiophenone (MDPBP), Benzedrone, 
Fluorotropacocaine, Benzocaine, Desoxypipradol, Pseudoephedrine, Lidocaine, 
Benzocaine,  3-Methiopropamine, Dimethylamylamine (DMAA), Stephanamine, 
Camfetamine,  4-Methylmethamphetamine, 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone 
(PVP), MDA 
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Analyses Performed by the National Laboratory During 2011 
 
Screening Sample 
Numbers 
2011 
Total number of urine samples screened by 
immunoassay 
157,957 
Total tests (screens by immunoassay) 1,029,922 
Blood Methadone levels (ELISA) 47 
 
Total Screens 
 
 
1,187,926 
 
 
 
 
Confirmatory Analysis Sample 
Numbers 
2011 
Opiate differentiation by LCMS  
(4 drugs) 
199 
Benzodiazepines differentiation by GC-MS (5 
drugs)  
466 
Zimovane identification by LCMS 2,057 
Buprenorphine identification by LCMS 199 
Headshop Drug Screen (over 40 drugs 
currently included - approx 15,700 drugs 
screened for in total in 2011) 
 
696 
 
Total Samples Confirmatory Analysis 
 
3,617 
 
 
 
Recent Key Achievements: 
 
 
– Our web-based system of Laboratory Electronic Reporting (LER) was made available to 
more of our customers in 2011. The system provides customers with an option to access 
their results more speedily since results are viewable in the system as soon as they have 
been authorised.   
 
– As part of a program of IT improvements and in order to enhance and streamline our IT 
systems, a novel project to remove “middleware” and directly connect our analysers to 
Labware LIMS was successfully completed in 2011. 
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– Using data from our unique “Head Shop” drugs screening the Laboratory contributed to 
the report: “Europol–EMCDDA Joint Report on a new psychoactive substance: 4-
methylmethcathinone (mephedrone)” and was referenced in the EMCDDA Risk 
Assessments 9: Report on the risk assessment of Mephedrone in the framework of the 
Council Decision on new psychoactive substances. EMCDDA 2011 and in the 2011 
NACD report “New Psychoactive Substances and the Outlets Supplying Them”. 
 
– As new “Head Shop” drugs emerged and as reference standards became available, the 
DTCB Laboratory “Head Shop” screen was expanded to include these drugs as required 
to meet clinical requirement. The Laboratory continues to monitor their usage. 
 
– In 2011 we validated immunoassay screening methods for the detection of drugs in Oral 
Fluid and an immunoassay method for detection of Ethyl Glucuronide in urine. 
 
– We presented a poster at the 2011 ACBI (Association of Clinical Biochemists of Ireland) 
Conference.  
 
– Our laboratory actively participated in the Early Warning and Emerging Trends (EWET) 
Committee of National Advisory Committee on Drugs (NACD) and in December 2011 
carried out analysis which was referenced in the  “HSE Warning: Severe reaction to 
ecstasy ingestion”  
 
– We participated in the first EMCDDA Trendspotter meeting in October 2011 on ‘Recent 
shocks in the European heroin market: explanations and ramifications’  which found that 
a small number of countries including Ireland experienced a severe shortage of heroin 
most heavily felt between November 2010 and March 2011. Our results show that there 
is an on-going reduction in either the availability or strength of Heroin in the market; 
however this has been counterbalanced by increased use of Benzodiazepines. 
 
– During 2011 we carried out a review of safety in the laboratory and implemented safety 
improvements. 
 
– Our Laboratory was represented at meetings of The International Association of Forensic 
Toxicologists (TIAFT) and at the UK Ireland Association of Forensic Toxicology 
(UKIAFT)  
 
– Our Principal Biochemist is the Irish Regional Representative for T.I.A.F.T. (The 
International Association of Forensic Toxicologists). 
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Client Services 
 
Primary Care Services 
 
Our primary care services are designed to: 
 
• Promote the health and well-being of clients through the provision of advice, information and 
education programmes. 
• Intervene at an early stage of illness thus decreasing the likelihood of the person needing acute 
admission to hospital.  
• Provide continuity of care in conjunction with general medical and psychiatric hospitals, 
maternity hospitals, general practitioners and HSE regions.   
 
 Provide joint care and treatment programmes with key services. 
 
 
We continue to provide a service that administers and monitors specialist medications, e.g. anti-
coagulant injections, general medical information, dietary advice and weight monitoring. 
Supervision of combination therapy medication for the treatment of HIV, as well as supervised 
administration of tuberculosis medications, is one of our key primary care services. 
 
 
 
General/Psychiatric Assessments 
 2011 
 
Number of 
Psychiatric 
Assessment 
Appointments  
 
 
 
250 
We carried out assessments on behalf of St. Michael’s Ward, Beaumont Hospital, Cuan Dara, 
Cherry Orchard Hospital, the Rutland Centre, General Practitioners and the Health Service 
Executive. This service supported the initiation of appropriate treatment interventions and 
facilitated individuals care to be managed at a local level. 
Walk in Initial/Emergency Services  
 2011 
 
Number of walk-in 
initial assessments  
 
 
 
80 
 
  
 
Children's Play Room  
 2011 
 
Number of visits to 
the play room 
 
 
1,694 
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Registered Nurse Prescribing 
 2011 
 
Number of Nurse 
prescribers 
 
 
2 
 
 
 
2007 saw the introduction of legislation giving prescriptive authority to Nurses and Midwives in 
Ireland.  In 2009, The Drug Treatment Centre Board was first to qualify a nurse prescriber in the 
field of addiction. Two Staff Nurses are now Registered Nurse Prescribers (RNP).  
 
One of the key documents relating to nurse prescribing is the Collaborative Practice Agreement 
(CPA). This is a written agreement drawn up between the RNP, a medical practitioner (approved 
by the health service provider/employer) and the health service provider (DTCB), outlining the 
parameters of the RNP’s prescriptive authority, i.e. their scope of practice. 
 
In addition there were ‘site requirements’ which included access to a Drug and Therapeutics 
Committee; appropriate risk management systems; a named mentor for each nurse; a prescribing 
site co-ordinator and a commitment to continuing education for nurse prescribers. We fulfilled 
these requirements and provide on-going local support and education for our RNP.  
 
According to the Nurse & Midwife Prescribing Data Collection System, our RNP’s, to date have 
prescribed 102 medications. This list consists of analgesics, non-steroidal anti-inflammatory 
medications and hepatitis vaccinations. This list is approved by the Drug and Therapeutics 
Committee and is due for review during 2012. 
 
Our Drug and Therapeutics Committee is a multi-disciplinary group and continues to support and 
advise on the proposed list of medications. For example, generic forms of medicinal product, 
authorised product, appropriate to clinical settings and scope of practice of Registered Nurse 
Prescriber and to ensure prescribing is in keeping with the organisations formulary and legislative 
requirements.  
 
 
Counselling 
 2011 
 
No of attendances 
for Counselling 
services 
 
 
 
2,040 
 
 
 
 
 
Social Work 
 2011 
 
No of attendances 
for Social Work 
services 
 
 
 
5,428 
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Welfare Service at the Drug Treatment Centre Board 
 2011 
Housing /Accommodation 510 
Med Cards/Travel 193 
Special/Dietary Al 190 
Gen Services 736 
  
Total 1629 
 
 
Non-Consultant Hospital Doctors 
 
We continue to provide specialist training to 14 Non Consultant Hospital Doctors (NCHD’s) and 
participate in training schemes accredited by The Royal College of Psychiatrists and the Irish 
College of General Practitioners. 
 
We provide placements for trainees participating in the Dublin University, St. John of God 
Hospital, the Mater and Connolly Hospital’s Training Rotation schemes.  These rotations are 
accredited by the Royal College of Psychiatrists and the Irish College of General Practitioners. 
 
 
 
      
February 2011 – Young Persons Programme (YPP) Open Day 
 
 
 
Ethics Committee 
 
 
 
 
 
 
 
 
Our Ethics Committee established since 2002 includes representation from medical, legal, 
nursing, management and lay people. 
 
 
 
 
 
 
 
 2011 
 
Number of 
proposals 
considered by the 
Ethics Committee 
 
 
 
 
12 
  18 
Research Publications 2011 
During 2011 our research publications included:- 
 
1. Ducray K., Byrne P., Burke., Smyth BP 
A comparison of the drug use patterns, measures of needs and quality of life of 
methadone-maintained patients using and not using cocaine 
Europad.org (www.europad.org) Heroin Addiction and Related Clinical Problems 2011; 
13 (3): 27-38  
 
 
2. Stokes, Siobhán 
Quantitative Evidence of a Heroin Drought. 
Drugnet Ireland, Health Research Board. Issue 40. Winter 2011 
 
Publications are available on our website http://www.dtcb.ie/research_training/publications.asp 
 
 
 
 
Student Placements 
 2011 
 
Number of student 
placements  
 
 
 
147 
 
 
As the longest established treatment service in the country, with more than 42 years of experience 
we have played a pivotal role in the on-going training and education of professionals for third 
level institutes, the HSE and other professionals in the area of substance misuse. This is achieved 
through formal training programmes, placements and educational presentations etc. Participants 
have the opportunity to see at first hand the many aspects of clinical services and treatment 
programmes, as well as our drug analysis laboratory.  These included nurses, social workers, 
counsellors, ambulance personnel, psychologists, childcare workers, laboratory, administrative 
and support services personnel.  In addition to student placements, clinical visits are also arranged 
for students and those working in the addiction field. 
 
 
Community Reinforcement Approach 
CRA (Community Reinforcement Approach) refers to the introduction and implementation of 
evidence based treatment approach to working with drug and alcohol users in Ireland. A key part 
of this is to get addiction specialists trained and supported to reach accreditation as CRA 
therapists for the very first time in Ireland.   
 
Our Senior Clinical Psychologist, Kevin Ducray is a qualified ACRA practitioner and is a 
member of the Blanchardstown Local Drugs Task Forces CRA. The Task Force commissioned 
one of the founders of the approach to deliver training in CRA for adults, ACRA for adolescent 
drug/alcohol users and the CRAFT model for families of drug and alcohol users.  Phase 1 of this 
plan saw an implementation team support over 80 addiction specialists to achieve accreditation as 
therapists in the model. In fact this is more than any other country in the world.  Kevin was one of 
a number of chairs who supported groups of trainees to develop their competencies and 
eventually satisfy the criteria to gain accreditation as qualified practitioners in the models.  
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2011 members of the Blanchardstown Local Drugs Task force CRA 
 
 
Risk Management  
Our Risk Management Committee, Clinical Governance Committee and Audit Committee 
continue to develop and implement effective risk management frameworks to assure that the full 
spectrum of risks are adequately managed in accordance with legal obligations and current best 
practices in the healthcare sector. 
 
Electronic Patient System (EPS) & EPSx 
The development of our bespoke Electronic Patient System (EPS) has continued over the years. 
In 2011 a feasibility study concerning the development of our system as the national HSE 
standard for care planning within addiction services was undertaken.  
The aim of this project was to pilot the DTCB EPS electronic health record in accordance with 
the recommendations contained in the Introduction of the Opioid Treatment Protocol: (HSE, 
2010:34) in order to determine its compatibility and potential use by community drug treatment 
services. In this way identified national problems concerning fragmented and demarcated 
provision of services which militate against HSE and NDS policy concerning the need for greater 
integration and continuity of care by adopting shared care planning and the development of 
integrated care pathways, can be addressed. The dearth of current monitoring and evaluation of 
addiction services was noted as well as the potential of EPS to provide for real time practice and 
the timely generation of statistics to inform policy and practice.  
It recommends that the EPSx system be rolled out nationally across all addiction services, 
based on the existing service provider model, which is deemed fit for purpose from practice 
and technical perspectives. The importance of instituting ongoing research and development 
as well as monitoring and evaluation was recognised as was the importance of feeding these 
results into national strategy fora. In 2012 we look forward to progressing this project 
nationally. 
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Staff fundraiser for Downs Syndrome Ireland. 27
th
 May 2011 
(L:R Pauline Geoghegan - Counsellor, Sheila Heffernan - CEO, Lorraine Shannon & Kathleen Fay – HR 
    
 
                        
 
Staff Fundraiser for the Irish Hospice 
Aileen Nestor & James Anderson   November 2011 Staff CPR Training 
 
                      
November 2011 Service of Remembrance 
Celebrant Fr. Paul St. John, 
The Immaculate Heart of Mary, City Quay.            Santa Visits The Drug Treatment Centre Board 
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Finance  
 
The finance department manages the annual allocation of HSE funding on behalf of the Board. 
The department ensures the timely payments to suppliers and monthly payroll to staff.  The 
department is also responsible for procurement of supplies in line with best practice. Finance 
ensures accurate reporting and cost control are maintained by production of reports including 
monthly accounts, annual financial statements and budgets.  Variance analysis and commentary is 
periodically provided to the Chief Executive Officer and the DTCB Board of Management. 
 
 
Financial Statements 
 
The financial statements for the year ended 2011 show total income of €8,800,271 of which 
€8,054,518 was the grant allocation from the Health Service Executive (HSE).  The 2011 
Financial Statements show a surplus of €77,510 in the year. (Note that this surplus is before 
taking into account a transfer of €946,495 from the Revenue to the Capital Account in 2011). 
 
 
External review of the systems of internal financial control  
 
In late 2011 the Board engaged an accounting firm to conduct an external review of its systems of 
internal financial control. The resulting report was approved by the Board in 2011.  A number of 
recommendations contained in the external review will be implemented by the board in 2012. 
 
 
Prompt Payment of Accounts Act (1997) 
 
It is the policy of our Board to comply with the Prompt Payment of Accounts Act (1997). The 
Drug Treatment Centre Board has systems and procedures to ensure full implementation of the 
provisions of the Prompt Payments of Accounts Act (1997).  Specific procedures are in place to 
enable the tracking of all transactions and payments in accordance with the terms of the Act and 
the relevant outputs from the accounting system are kept under continuous review. The Board’s 
procedures, which conform to accepted best practice, provide reasonable, but not absolute 
assurance, against non-compliance with the Act. It is also our practice to review and to take 
appropriate action in relation to any incidents of non-compliance that may arise. In 2011 the 
Board fully complied with the provisions of the Act and we are pleased to report that the Board 
was not liable for any interest payments to creditors. 
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